Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 447-920-2 | CAS number: 897393-42-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2003-03-19 - 2003-07-02
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Cross-reference
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 003
- Report date:
- 2003
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Version / remarks:
- (1997)
- Deviations:
- yes
- Remarks:
- minor modifications cytogenetic assay as described by Evans, 1984
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.10 (Mutagenicity - In Vitro Mammalian Chromosome Aberration Test)
- Version / remarks:
- Directive 2000/32/EC, Part B
- Deviations:
- yes
- Remarks:
- minor modifications cytogenetic assay as described by Evans, 1984
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian chromosome aberration test
Test material
- Test material form:
- liquid
- Details on test material:
- - Batch: 8191-34
- Purity: 97.8% (expressed as primary amine, % of total)
Constituent 1
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): XTJ 568
- Physical state: clear colourless liquid
- Analytical purity: 97.8%
- Impurities (identity and concentrations): no data
- Purity test date: no data
- Lot/batch No.: 8191-34
- Expiration date of the lot/batch: 01 January 2004
- Stability under test conditions: no data
- Storage condition of test material: at room temperature in the dark. Stable under storage conditions
- Other: specific gravity: > 0.94 g/cm3
Method
Species / strain
- Species / strain / cell type:
- lymphocytes: human peripheral
- Details on mammalian cell type (if applicable):
- - Type and identity of media: F10 complete culture medium consisted of Ham's F10 medium with thymidine and hypoxanthine (Gibco), supplemented with 20% (v/v) heatinactivated (56°C; 30 min) foetal calf serium (Gibco), L-glutamine (2 mM), penicillin/streptomycin (50 U/mL and 50 µg/mL respectively), sodium bicarbonate (1.2 g/L) and 30 U/mL heparin
- Properly maintained: yes: all incubations were carried out in a humid atmosphere (80-100%) containing 5± 0.5% CO2 in air in the dark at 37 ± 1°C. The temperature, humidity and CO2- percentage were monitored throughout the experiment
- Periodically checked for Mycoplasma contamination: no data
- Periodically checked for karyotype stability: no data
- Periodically "cleansed" against high spontaneous background: no data
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9-mix of liver rat induced with Aroclor-1254.
- Test concentrations with justification for top dose:
- Concentration range in the first main test (with metabolic activation): 333, 666 and 1000 µg/ml (3h exposure, 24h fixation)
Concentration range in the second main test (with metabolic activation): 100, 666 and 1250 µg/ml (3h exposure, 48h fixation)
Concentration range in the first main test (without metabolic activation): 333, 666 and 1000 µg/ml (3h exposure, 24h fixation)
Concentration range in the second main test (without metabolic activation): 100, 500 and 800 µg/ml (24h exposure, 24h fixation)
Concentration range in the second main test (without metabolic activation): 700, 850 and 875 µg/ml (48h exposure, 48h fixation) - Vehicle / solvent:
- F10 medium buffered with 20 mM HEPES
Controlsopen allclose all
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- F10 medium buffered with 20 mM HEPES
- True negative controls:
- no
- Positive controls:
- no
- Positive control substance:
- mitomycin C
- Remarks:
- without metabolic activation
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- F10 medium buffered with 20 mM HEPES
- True negative controls:
- no
- Positive controls:
- no
- Positive control substance:
- cyclophosphamide
- Remarks:
- with metabolic activation
- Details on test system and experimental conditions:
- Experiment 1:
With/without S9: 3h exposure and 24h fixation time.
Experiment 2: With S9: 3h exposure and 48h fixation time. Without S9: 24h and 48h exposure time, 24h and 48h fixation time.
SPINDLE INHIBITOR (cytogenetic assays): colchicine
NUMBER OF REPLICATIONS: duplicates
NUMBER OF CELLS EVALUATED: at least 100 metaphase chromosome spreads per culture
DETERMINATION OF CYTOTOXICITY
- Method: mitotic index of each culture was determined by counting the number of metaphases per 1000 cells.
- Determination of polyploidy: yes
- Determination of endoreplication: yes - Evaluation criteria:
- A test substance was considered positive (clastogenic) in the chromosome aberration test if:
a) it induced a dose-related statistically significant (Chi-square test, P < 0.05) increase in the number of cells with chromosome aberrations
b) a statistically significant increase in the frequencies of the number of cells with chromosome aberrations was observed in the absence of a clear dose-response relationship
A test substance was considered negative (not clastogenic) in the chromosome aberration test if none of the tested concentrations induced a statistically significant (Chi-square test, P< 0.05) increase in the number of cells with chromosome aberrations. - Statistics:
- The incidence of aberrant cells (cells with one or more chromosome aberrations, inclusive or exclusive gaps) for each exposure group was compared to that of solvent control using Chi-square statistics:
X2=[(N-1) x (ad-bc)^2]/[(a+b) (c+d) (a+c) (b+d)]
b= total number of aberrant cells in control cultures
d = total number of non aberrant cells in control cultures
n0 = total number of cells scored in the control cultures
a = total number of aberrant cells in treated cultures to be compared with the control
c = total number of non aberrant cells in treated cultures to be compared with the control
n1 = the total number of cells scored in the treated cultures
N = sum of n0 and n1
If P [X2> [(N-1) x (ad-bc)^2]/[(a+b) (c+d) (a+c) (b+d)] (two-tailed) is small (P<0.05) the hypothesis that the incidence of cells with chromosome aberrations is the same for both the treated and the solvent control group is rejected and the number of aberrant cells in the test group is considered to be significantly different from the control group at the 95% confidence level.
Results and discussion
Test results
- Key result
- Species / strain:
- lymphocytes: human peripheral
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- Observations: In the first cytogenetic assay the test substance increased
the number of polyploid cells both in the absence and
presence of S9-mix. This may indicate that the test
substance has the potential to disturb mitotic processes and
cell cycle progression, thereby inducing numerical
chromosome aberrations.
The pH and osmolarity of a concentration of 100 µg/mL were 7.73 and 291 mOsm/kg respectively (compared to 7.51 and 290 mOsm/kg in the solvent control). The pH and osmolarity of this concentration was not measured in the first cytogenetic assay.
RANGE-FINDING/SCREENING STUDIES: The pH and osmolarity of a concentration of 5000 µg/mL were 10.01 and 305 mOsm/kg respectively (compared to 7.42 and 284 mOsm/kg in the solvent control). In the dose range finding test blood cultures were treated with 100, 333, 1000, 3330 and 5000 µg XTJ 568/mL culture medium with and without S9-mix.
COMPARISON WITH HISTORICAL CONTROL DATA: The number of cells with chromosome aberrations found in the solvent control culture were within the laboratory historical control data range {min=0, max=6 (mean=1.1, standard deviation: 1.1) aberrant cells per 100 metaphases in the absence of S9-mix; gaps excluded and min=0, max=5 (mean=0.9, standard deviation=1.0) aberrant cells per 100 metaphases in the presence of S9-mix; gaps excluded; for n=660 and 437 respectively}. - Remarks on result:
- other: all strains/cell types tested
Applicant's summary and conclusion
- Conclusions:
- The substance is not clastogenic in human lymphocytes under the experimental conditions tested. In the first cytogenetic assay, the substance increased the number of polyploid cells (with and without S9) indicating a potential to disturb mitotic processes and cell cycle progression, thereby inducing numerical chromosome aberrations.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
This website uses cookies to ensure you get the best experience on our websites.
Find out more on how we use cookies.